Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study
- PMID:20691481
- DOI: 10.1016/j.jad.2010.06.031
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study
Abstract
Background: Evaluate the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) once-daily monotherapy for patients with major depressive disorder (MDD).
Methods: In this 10-week, (8-week active treatment phase and 2-week drug-discontinuation/tapering phase), multicenter, parallel-group, placebo-controlled, double-blind, randomized, Phase III study (D1448C00003: Opal), patients initially received quetiapine XR 150 mg/day or placebo. At Week 2, inadequate responders (<20% reduction in MADRS total score) were up-titrated to 300 mg/day quetiapine XR or matching placebo for the final 6 weeks. Primary endpoint: change from randomization to Week 8 in MADRS total score. Secondary endpoints included: MADRS response (≥50% reduction in total score from randomization) and changes from randomization to Week 8 in HAM-D and CGI-S.
Results: 310 patients were randomized. At Week 8, quetiapine XR significantly reduced mean MADRS total score versus placebo (-16.49 vs -13.10, respectively; p<0.01). Mean MADRS score was significantly reduced by quetiapine XR versus placebo at Week 1 (p<0.05). MADRS response rates were significantly greater at Week 8 for quetiapine XR versus placebo (61.9% vs 48.0%, respectively; p<0.05). Significant changes in HAM-D total score and CGI-S were seen at Week 8 for quetiapine XR versus placebo. Withdrawal rates due to AEs were 9.9% and 2.6% for quetiapine XR and placebo, respectively. Common AEs (>10% any group during the randomized phase) for quetiapine XR and placebo, respectively were dry mouth (32.9% and 6.5%), sedation (21.7% and 1.9%), somnolence (20.4% and 5.2%), and headache (10.5% and 10.3%).
Limitations: The study was not designed to compare quetiapine XR 150 mg/day and 300 mg/day; it was intended to reflect dose titration that might occur in clinical practice.
Conclusions: Quetiapine XR monotherapy is effective in patients with MDD, with symptom improvement seen as early as Week 1, and tolerability results consistent with the known profile of quetiapine.
Trial registration: ClinicalTrials.govNCT00326144.
Copyright © 2010. Published by Elsevier B.V.
Similar articles
- Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H.Liebowitz M, et al.Depress Anxiety. 2010 Oct;27(10):964-76. doi: 10.1002/da.20740.Depress Anxiety. 2010.PMID:20734365Clinical Trial.
- Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, Datto C.Katila H, et al.Am J Geriatr Psychiatry. 2013 Aug;21(8):769-84. doi: 10.1016/j.jagp.2013.01.010. Epub 2013 Feb 6.Am J Geriatr Psychiatry. 2013.PMID:23567397Clinical Trial.
- Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate.Sheehan DV, Locklear J, Svedsäter H, Datto C.Sheehan DV, et al.Int Clin Psychopharmacol. 2012 Sep;27(5):239-48. doi: 10.1097/YIC.0b013e328356ac78.Int Clin Psychopharmacol. 2012.PMID:22859063Clinical Trial.
- Quetiapine XR: current status for the treatment of major depressive disorder.Pae CU, Sohi MS, Seo HJ, Serretti A, Patkar AA, Steffens DC, Masand PS.Pae CU, et al.Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1165-73. doi: 10.1016/j.pnpbp.2010.03.023. Epub 2010 Mar 20.Prog Neuropsychopharmacol Biol Psychiatry. 2010.PMID:20307622Review.
- Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.Figueroa C, Brecher M, Hamer-Maansson JE, Winter H.Figueroa C, et al.Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):199-204. doi: 10.1016/j.pnpbp.2008.09.026. Epub 2008 Oct 9.Prog Neuropsychopharmacol Biol Psychiatry. 2009.PMID:18948162Review.
Cited by
- Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders.El-Khalili N.El-Khalili N.Neuropsychiatr Dis Treat. 2012;8:523-36. doi: 10.2147/NDT.S14369. Epub 2012 Nov 8.Neuropsychiatr Dis Treat. 2012.PMID:23152684Free PMC article.
- A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder.Wang G, McIntyre A, Earley WR, Raines S, Eriksson H.Wang G, et al.Psychopharmacol Bull. 2012 Feb 15;45(1):5-30.Psychopharmacol Bull. 2012.PMID:27738365Free PMC article.
- The management of schizophrenia: focus on extended-release quetiapine fumarate.Peuskens J.Peuskens J.Neuropsychiatr Dis Treat. 2011;7:549-64. doi: 10.2147/NDT.S3380. Epub 2011 Sep 21.Neuropsychiatr Dis Treat. 2011.PMID:22003295Free PMC article.
- Early post-treatment blood oxygenation level-dependent responses to emotion processing associated with clinical response to pharmacological treatment in major depressive disorder.Williams RJ, Brown EC, Clark DL, Pike GB, Ramasubbu R.Williams RJ, et al.Brain Behav. 2021 Aug;11(8):e2287. doi: 10.1002/brb3.2287. Epub 2021 Aug 1.Brain Behav. 2021.PMID:34333866Free PMC article.
- Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview.Pompili M, Baldessarini RJ, Forte A, Erbuto D, Serafini G, Fiorillo A, Amore M, Girardi P.Pompili M, et al.Int J Mol Sci. 2016 Oct 11;17(10):1700. doi: 10.3390/ijms17101700.Int J Mol Sci. 2016.PMID:27727180Free PMC article.Review.
Publication types
MeSH terms
Substances
Associated data
Related information
LinkOut - more resources
Full Text Sources